TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4635-4639

  Peters Engl, Christian ^a   Buxbaum, Pia ^a   Ogris, Emil ^b   Sevelda, Paul ^a   Medl, Michael ^a,c  

^a GENERAL HOSPITAL LINZ   (Austria)

^b Neurological Department   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

CA 125; Endometrial cancer; TATI

Indexed keywords

APROTININ; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MYOMETRIUM; PELVIS INJURY; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0032407706     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gaducci A, Ferdeghini M, Prontera C, Giordano P Cristofani R, Bianchi R and Fioretti P: A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. Eur J Gynaecol Oncol 11(4): 283-288, 1990.
2. Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, Yamauchi K and Hasumi K: Combined assay of serum levels of CA 125 and CA 19-9 in endometrial carcinoma. Gynecol Oncol 54(3): 321-326, 1994.
3. Duk JM, Aalders JG, Fleuren GJ et al: CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155: 1097-1102, 1986.
4. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC and Bast RC: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium and endocervix. Am J Obstet Gynecol 148: 1057-1058, 1984.
5. Stenman UH, Huhtala ML, Koistinen R and Seppala M: Immunohistochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 30: 53-57, 1982.
6. Huhtala ML, Personen K, Kalkkinen N and Stenman UH: Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257: 13713-3716, 1982.
7. Hulitala ML, Kahanpaa K, Seppala M, Halila H and Stenman UH: Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients. With gynecological malignancy. Int J Cancer 31: 711-714, 1983.
8. Koivunen E, Huhtala ML and Stenman UH: Human ovarian tumor-accociated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of prourokinase. J Biol Chem 264: 14095-14099, 1989.
9. Mogensen O, Mogensen B, and Jakobsen A: Tumor associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumors. Br J Cancer 61: 327-329, 1990.
10. Peters-Engl C, Medl M, Ogris E and Leodolter S: Tumor-Associated Trypsin Inhibitor (TATI) and Cancer Antigen 125 (CA125) in Patients with Epithelial Ovarian Cancer. Anticancer Res 15: 2727-2730, 1995.
11. Medl M, Ogris E, Peters-Engl C and Leodolter S: TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. Br J Cancer 71: 1051-1054, 1995.
12. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R and Fiorettia P: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 44: 147-154, 1992.
13. Gaducci A, Ferderghini M, Facchini V, Ceccarini T, Prontera C, Bianchi R and Fioretti P: A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecologic pathology. Eur J Gynaecol Oncol 11(2): 111-115, 1990.
14. Inaudi P, Petrilli S De-Leo, V, Bernabei A, Pasqui L and D'Antona N: Evaluatiom of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease. Scand J Clin Lab Invest suppl 207: 11-13, 1991.
15. Tone GC, Rembado R, Barbetti V, Viglierco GP, Foglia M, Calabrese A and Corongiu F: Serumlevels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. Scand 3 Lab Invest Suppl 207: 15-18, 1991.
16. Creasman WT: New gynecologic cancer staging. Obstet Gynecol 75: 287-288, 1990.
17. Klug TL, Bast RC, Niloff JM, Knapp RC and Zurawski VR: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44: 1048-1053, 1984.
18. Sato K, Mizuuchi H, Mori Y, Okamura N, Endo T, Kudo R and Tsukamoto K: Management of uterine endometrial cancer cases whose cytological and histological specimens cannot be obtained from the uterine cavity - assessment by CA125 or vaginal ultrasonography. Nippon Sanka Fujinka Gakkai Zasshi 46(6): 517-524, 1994.
19. Lehtovira P, Cacciatore B and Ylostalo P: Serum CA 125 levels and sonography in the pre-operative assessment of myometrial invasion of endometrial cnacer. Br J Obst Gynaecol 101: 532-535, 1994.
20. Beck EP, Wagner M, Anselmino L Xu F, Bast RC and Jaeger W: Is OVX1 a suitablee marker for endometrial cancer. Gynecol Oncol 65(2): 291-196, 1997.
21. Paavonen J, Lehtinen M, Lehto M, Aine R, Rasanen L and Stenman UH: Concentration of tumor-associated trypsin inhibitor and C-reactive protein in acute pelvic inflammatory disease. Clin Chem 35: 869-871, 1989.